• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新突变的出现及其在拓扑异构酶 IV 基因中的积累赋予了大肠杆菌分离株对氟喹诺酮类药物的高度耐药性。

Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.

机构信息

Department of Microbiology, Kyungpook National University School of Medicine, #101, Dongin-dong-2 ga, Jung-gu, Daegu 700-422, Republic of Korea.

出版信息

Int J Antimicrob Agents. 2010 Jan;35(1):76-9. doi: 10.1016/j.ijantimicag.2009.08.003. Epub 2009 Sep 24.

DOI:10.1016/j.ijantimicag.2009.08.003
PMID:19781915
Abstract

Mutations in DNA gyrase and topoisomerase IV genes are the main mechanisms of resistance to quinolones. In this study, we determined mutations in gyrA, gyrB, parC and parE among 57 ciprofloxacin-resistant Escherichia coli isolates from a South Korean hospital and analysed the relationship between the minimal inhibitory concentrations (MICs) of fluoroquinolones and mutations in the topoisomerase IV gene. All ciprofloxacin-resistant E. coli isolates carried double mutations in gyrA and at least a single mutation in parC; some isolates also carried a single mutation in parE. The most common mutations were S83L and D87N in gyrA, S80I in parC and S458A in parE, which accounted for 25% of isolates. Single mutations in parE at L445I, S458P and S458W were identified for the first time. Double mutations in parC and a combination of single mutations in parC and parE significantly increased the MIC values of fluoroquinolones. In vitro induction of resistance to ciprofloxacin showed that double mutations in gyrA were a prerequisite to conferring a resistant phenotype to fluoroquinolones, and an additional mutation in the topoisomerase IV gene increased the MIC values of ciprofloxacin. In conclusion, emergence of a new mutation in parC and parE and its accumulation induces high levels of resistance to fluoroquinolones in E. coli.

摘要

DNA 回旋酶和拓扑异构酶 IV 基因突变是喹诺酮类药物耐药的主要机制。在这项研究中,我们确定了韩国一家医院的 57 株环丙沙星耐药大肠杆菌中 gyrA、gyrB、parC 和 parE 基因的突变,并分析了拓扑异构酶 IV 基因突变与氟喹诺酮类药物最小抑菌浓度(MIC)之间的关系。所有环丙沙星耐药的大肠杆菌分离株均在 gyrA 中携带双重突变,至少在 parC 中有一个单一突变;一些分离株还携带 parE 的单一突变。最常见的突变是 gyrA 中的 S83L 和 D87N、parC 中的 S80I 和 parE 中的 S458A,占分离株的 25%。首次在 parE 中发现了 L445I、S458P 和 S458W 的单一突变。parC 中的双重突变和 parC 和 parE 中的单一突变的组合显著增加了氟喹诺酮类药物的 MIC 值。体外诱导对环丙沙星的耐药性表明,gyrA 中的双重突变是赋予氟喹诺酮类药物耐药表型的先决条件,拓扑异构酶 IV 基因中的额外突变增加了环丙沙星的 MIC 值。总之,parC 和 parE 中新突变的出现及其积累导致大肠杆菌对氟喹诺酮类药物的高水平耐药。

相似文献

1
Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.新突变的出现及其在拓扑异构酶 IV 基因中的积累赋予了大肠杆菌分离株对氟喹诺酮类药物的高度耐药性。
Int J Antimicrob Agents. 2010 Jan;35(1):76-9. doi: 10.1016/j.ijantimicag.2009.08.003. Epub 2009 Sep 24.
2
Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.从鸡中分离的大肠杆菌的氟喹诺酮耐药性及gyrA和parC基因突变
J Microbiol. 2005 Oct;43(5):391-7.
3
Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.DNA 回旋酶和拓扑异构酶 IV 基因突变对大肠杆菌临床分离株中环丙沙星耐药性的贡献。
Int J Antimicrob Agents. 2011 Mar;37(3):253-5. doi: 10.1016/j.ijantimicag.2010.11.022. Epub 2011 Jan 13.
4
Geographic distribution of fluoroquinolone-resistant Escherichia coli strains in Asia.亚洲地区氟喹诺酮耐药大肠埃希菌的地理分布。
Int J Antimicrob Agents. 2010 Apr;35(4):387-91. doi: 10.1016/j.ijantimicag.2009.12.005.
5
[Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].[鼠伤寒沙门氏菌分离株拓扑异构酶基因中的氟喹诺酮抗性突变]
Wei Sheng Yan Jiu. 2004 Sep;33(5):591-4.
6
The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.伤寒沙门氏菌通过拓扑异构酶靶点的点突变积累获得对氟喹诺酮类药物的完全耐药性。
J Antimicrob Chemother. 2006 Oct;58(4):733-40. doi: 10.1093/jac/dkl333. Epub 2006 Aug 8.
7
Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.铜绿假单胞菌环丙沙星耐药临床分离株中拓扑异构酶II的GyrA和GyrB亚基以及拓扑异构酶IV的ParC和ParE亚基的改变。
Int J Antimicrob Agents. 2005 Apr;25(4):290-5. doi: 10.1016/j.ijantimicag.2004.11.012.
8
Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.泌尿道病原体中氟喹诺酮耐药机制的分析。
J Antimicrob Chemother. 2006 Dec;58(6):1274-8. doi: 10.1093/jac/dkl404. Epub 2006 Oct 13.
9
Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.DNA 回旋酶和拓扑异构酶 IV 基因突变导致霍乱弧菌 O139 菌株对氟喹诺酮类药物的耐药性增加。
Int J Antimicrob Agents. 2013 Jul;42(1):72-5. doi: 10.1016/j.ijantimicag.2013.03.004. Epub 2013 May 1.
10
Mutations in the gyrB, parC, and parE genes of quinolone-resistant isolates and mutants of Edwardsiella tarda.产酸克雷伯菌喹诺酮类耐药株和突变株中 gyrB、parC 和 parE 基因突变。
J Microbiol Biotechnol. 2010 Dec;20(12):1735-43.

引用本文的文献

1
The effect of commonly used non-antibiotic medications on antimicrobial resistance development in Escherichia coli.常用非抗生素药物对大肠杆菌耐药性产生的影响。
NPJ Antimicrob Resist. 2025 Aug 25;3(1):73. doi: 10.1038/s44259-025-00144-w.
2
Ribosome phenotypes for rapid classification of antibiotic-susceptible and resistant strains of Escherichia coli.用于快速分类大肠杆菌抗生素敏感和耐药菌株的核糖体表型
Commun Biol. 2025 Feb 26;8(1):319. doi: 10.1038/s42003-025-07740-6.
3
Navigating fluoroquinolone resistance in Gram-negative bacteria: a comprehensive evaluation.
应对革兰氏阴性菌中的氟喹诺酮耐药性:全面评估
JAC Antimicrob Resist. 2024 Aug 14;6(4):dlae127. doi: 10.1093/jacamr/dlae127. eCollection 2024 Aug.
4
MetaQuad: shared informative variants discovery in metagenomic samples.MetaQuad:宏基因组样本中共享信息变异的发现
Bioinform Adv. 2024 Feb 24;4(1):vbae030. doi: 10.1093/bioadv/vbae030. eCollection 2024.
5
Prevalence and mechanisms of ciprofloxacin resistance in Escherichia coli isolated from hospitalized patients, healthy carriers, and wastewaters in Iran.伊朗住院患者、健康携带者和废水中分离的大肠杆菌对环丙沙星耐药的流行情况及其机制。
BMC Microbiol. 2023 Jul 17;23(1):191. doi: 10.1186/s12866-023-02940-8.
6
Insights into coastal microbial antibiotic resistome through a meta-transcriptomic approach in Yucatan.通过元转录组学方法对尤卡坦半岛沿海微生物抗生素抗性组的洞察。
Front Microbiol. 2022 Oct 17;13:972267. doi: 10.3389/fmicb.2022.972267. eCollection 2022.
7
Targeting the Holy Triangle of Quorum Sensing, Biofilm Formation, and Antibiotic Resistance in Pathogenic Bacteria.针对病原菌群体感应、生物膜形成和抗生素耐药性的“神圣三角”
Microorganisms. 2022 Jun 16;10(6):1239. doi: 10.3390/microorganisms10061239.
8
Characterization of qnrB-carrying plasmids from ESBL- and non-ESBL-producing Escherichia coli.qnrB 携带质粒的特征来自产 ESBL 和非产 ESBL 的大肠杆菌。
BMC Genomics. 2022 May 12;23(1):365. doi: 10.1186/s12864-022-08564-y.
9
Genomic and Phenotypic Characterization of a Colistin-Resistant Isolate Co-Harboring , and Isolated from Urine.一株同时携带、和且从尿液中分离出的耐黏菌素菌株的基因组和表型特征分析
Infect Drug Resist. 2022 Mar 29;15:1329-1343. doi: 10.2147/IDR.S355010. eCollection 2022.
10
Antimicrobial Resistance and Molecular Epidemiology of Uropathogenic Isolated From Female Patients in Shanghai, China.中国上海女性患者分离的尿路致病性菌株的抗菌耐药性及分子流行病学研究。
Front Cell Infect Microbiol. 2021 Aug 13;11:653983. doi: 10.3389/fcimb.2021.653983. eCollection 2021.